Patient Controlled Analgesia Pharmacogenetic Study
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Non-Interventional Pharmacogenetic Study of Patient / Proxy Controlled Analgesia in Children Undergoing Surgery|
- Number of adverse events [ Time Frame: 48 hours post-operatively ] [ Designated as safety issue: Yes ]Postoperative incidence of significant central adverse effects to opioids (respiratory depression, excessive sedation and postoperative nausea and vomiting - PONV)
- Post-operative pain [ Time Frame: 48 hours postoperatively ] [ Designated as safety issue: No ]Post-surgical pain scores at rest and on mobilization, opioid requirements/48 hours postoperatively.
Biospecimen Retention: Samples With DNA
|Study Start Date:||May 2011|
|Estimated Study Completion Date:||December 2015|
|Estimated Primary Completion Date:||December 2015 (Final data collection date for primary outcome measure)|
Opioids are the mainstay for treatment of postoperative pain in children. Experience dictates that opioids have narrow therapeutic indices and large inter-patient variability in response. This leads to serious side effects like respiratory depression in up to 50% of children undergoing invasive surgery, which can be fatal. Moreover, up to two-thirds of the inter-individual variability in response to opioids results from genetic variations both from variability in pain perception as well as response to the pain medicine. Much of the inter-individual variability in response to opioids following surgical procedures can be explained by single nucleotide polymorphisms (SNPs) in a subset of the genes that encode proteins involved in pain perception, opioid transport/metabolism (pharmacokinetics) and opioid receptor signaling (pharmacodynamics). It is evident that there are particular children who are more susceptible to suffering side effects and having inadequate pain relief from opioids. Identifying genetic and non-genetic predictors for this susceptibility is vital for safe and effective analgesia in children. This is a critical knowledge gap in medical literature that significantly impacts pediatric pain management. The investigators' central hypothesis is that specific genetic polymorphisms in genes involved in pain perception, opioid transport and opioid receptor signaling pathways contribute significantly to pain sensitivity, opioid side-effects and analgesic efficacy in children.
The choice and dosing of opioids has thus far been largely empirical, with a frequent need to switch opioids and alter doses due to inherent differences in individuals. By this study, the investigators hope to determine the 'right' doses of the 'right' opioids for optimized and safe postoperative analgesia in children.
The investigators' long term goal is to develop more effective, safer and tailored pediatric opioid analgesia, by contributing to better understanding of the underlying genetic basis for variations in the sensitivity to pain, pain relief, and development of adverse effects from the extended use of postoperative intravenous opioids, in children.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01731873
|United States, Ohio|
|Cincinnati Childrens Hospital Medical Center|
|Cincinnati, Ohio, United States, 45229|
|Principal Investigator:||Vidya Chidambaran, MD||Cincinnati Childrens Hospital Medical Center|